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Human immunodeficiency virus–infected people discontinuing
therapy experience a rebound in the virus level (hereafter, “re-
bound virus”) from a persistent reservoir. We examined 10
samples from patients in AIDS Clinical Trials Group study
A5068 with rebound virus, using single-genome amplification
and Primer ID deep sequencing, to assess env genetic diversity
of the virus population. Most rebound-virus populations
showed significant diversity. All env examined required high
levels of CD4 for entry, consistent with selection of replication
in CD4+ T cells. These results indicate that most people discon-
tinuing therapy release a diverse population of virus and that
this released virus has entry features of virus selected for repli-
cation in CD4+ T cells, rather than in myeloid cells.
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Successful antiretroviral therapy (ART) reduces the human im-
munodeficiency virus type 1 (HIV-1) load in the blood to stable
low levels; however, ART does not eliminate virus. Most people
discontinuing therapy experience a rebound in the virus level
(hereafter, “rebound virus”) from a persistent reservoir [1–4].
The variable timing of rebound, where the virus is coming
from, and the complexity of the rebound virus population are
poorly understood.
One potential source of virus is latently infected resting CD4+
T cells. There is also a continual production of virus at low levels
despite ART, and other cell types could be the source of re-
bound virus. In a largely quiescent reservoir, rebound virus
could be clonal, as the result of virus from a single cell leaving
a latent state. However, the number and complexity of rebound
virus within a person has recently been predicted to be much
higher than predicted on the basis of a largely quiescent reser-
voir [4].
To this end, we used peripheral blood samples from patients
in AIDS Clinical Trials Group study A5068 [5] to investigate the
diversity and entry phenotype of rebound virus. Subjects in
A5068 discontinued ART as part of an analytic treatment inter-
ruption (ATI) and had virologic rebound detectable in the
blood 2–4 weeks, on average, after discontinuation of therapy.
To study the complexity of rebound virus, we assessed the ge-
netic diversity of viral env and also examined viral entry pheno-
type. Phylogenetic analysis showed a high degree of diversity in
the rebound virus population. In addition, all Env examined re-
quired high levels of CD4 for efficient entry, consistent with
prior selection for replication in CD4+ T cells. Our analysis sug-
gests that a viral population replicating in myeloid cells is not a
significant source of rebound virus in blood early after the dis-
continuation of ART.
METHODS
A detailed description of the study methods is available in the
Supplementary Materials. The parent trial is registered at Clin-
icalTrials.gov (registration NCT00011011).
Study Population
All samples were collected under institutional review board–
approved protocols, and all subjects provided written
informed consent. AIDS Clinical Trials Group study A5068
examined whether structured treatment interruptions and/or
vaccination with an ALVAC-HIV vector was associated with
control of viral replication during a subsequent ATI, compared
with no vaccination or structured interruption control (arm A).
The study showed a modest effect in reduced peak and set point
viral load of rebound virus in the arms that included the struc-
tured treatment interruptions [5]. Subjects with the ATI only
(arm A) had a median CD4+ T-cell count of 779 copies/mL
and viral RNA levels of <50 copies per mL at entry while still
receiving therapy. For our study, we used blood plasma samples
from 10 of these subjects early after the initiation of the ATI,
when viral load was ≥1000 copies/mL. For one subject, a pre-
therapy sample was also available.
Virus Characterization
Sequences of virion RNA were examined using single-genome
amplification (SGA) [6] of full-length env and deep sequencing
with Primer ID [7] of the V1–V3 region of env. Phylogenetic
analysis of full-length env was used to select a representative
sampling of amplicons for cloning to assess viral entry
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phenotype. env cloned in an expression vector was used in co-
transfection with the pNL4–3.LucR-E reporter backbone plas-
mid into 293 T cells to generate an Env-pseudotyped
luciferase reporter virus as described previously [8–10].By com-
paring the ability of the pseudotyped virus to infect Affinofile
cells expressing high versus low levels of surface CD4, we are
able to consistently assess the viral CD4 entry phenotype as
largely restricted to CD4+ T cells when high levels of CD4 are
required for entry (T-cell tropic), compared with tropism favor-
ing cells with a low density of CD4, such as macrophages (mac-
rophage tropic) [8]. Sensitivity to soluble CD4 (sCD4) was used
to confirm the CD4 entry phenotype. Additionally, coreceptor
use was analyzed using Maraviroc inhibition of CCR5.
RESULTS
We analyzed 11 plasma samples from 10 subjects (subject
43 656 had a pretherapy [R0] and rebound [R1] sample avail-
able; Figure 1A). We used plasma from the first available time
point at which the viral load was >1000 copies/mL, to focus on
early rebound virus, with most samples yielding a viral load of
<10 000 copies/mL (Figure 1B). Eight of ten subjects had nadir
CD4+ T-cell counts before therapy of 201–500 cells/mL, while 1
(sample R10) was <201 cells/mL.
To determine the viral sequence diversity of the rebound
samples, we performed deep-sequencing analysis with Primer
ID to sequence the V1–V3 region of env [7] (Figure 1D), in ad-
dition to doing SGA of full-length env [6]. Deep-sequencing re-
sults were achieved for 8 of 10 rebound samples and the
pretherapy sample (however, the rebound sample, R1, from
the patient from whom the pretherapy sample was obtained
did not yield deep-sequencing results). We estimated the min-
imum number of rebound viruses as distinct sequence lineages
in the phylogenetic tree analysis and highlighter plots (Fig-
ures 1D and 2A and Supplementary Figures 1 and 2). We
used both distinct lineages and complex clusters of linked se-
quence differences in forming this estimate while trying to
avoid interpreting complexity that could have been the result
of postrebound recombination. We consider these values as
minimum estimates of rebound virus complexity since the vi-
ruses considered as potential recombinants could have preexist-
ed in the reservoir and been independently reactivated. Analysis
of the minimum number of lineages versus the time (in weeks)
to rebound demonstrated no obvious correlation between the
time to rebound and the complexity of the rebound virus pop-
ulation (Figure 1C). For virus that rebounded in the first few
weeks, we estimated 1–5 distinct lineages by deep sequencing,
with a mean of 3.1 lineages, for these early rebound viruses.
R2 took the longest to rebound (10 weeks) and showed a rela-
tively low diversity, with only 2 lineages. SGA of full-length env
showed 1–4 distinct lineages, with a mean of 3.1 lineages, similar
to the results obtained with deep sequencing (Figure 1C). The
mean intrapatient diversity was also determined by pair-wise
analysis using full-length env and was found to be 0.2%–3.1%.
Additional analyses of 10 subjects with early phase infection
(Supplementary Table 2) [11] and 7 with chronic infection
who were not receiving therapy (unpublished data; Supple-
mentary Table 3) were also done, revealing mean intrapati-
ent diversity of 0.16%–1.2% (Supplementary Figure 3) and
1.1%–4.1%, respectively. These numbers suggest that rebound
virus is more similar to virus in chronically infected subjects,
in whom multiple viral lineages form a genetically complex
population.
We subsequently cloned 51 individual env genes (average, 4
amplicons/subject) from the major lineages in each participant
to determine the entry phenotype of rebound virus, using the
Affinofile cell line (Figure 2A and Supplementary Figure 2).
The pretherapy sample (R0) was also included; no clones
were obtained for sample R5. Affinofile cells allow controlled
expression of CD4 and are currently the most consistent meth-
od to assess CD4-dependent entry phenotype [8]. Entry pheno-
type was evaluated on the basis of the ability of viruses
pseudotyped with Env from rebound virus to infect Affinofile
cells expressing either high or low levels of CD4. The phenotype
was confirmed by sensitivity to inhibition by sCD4 at a concen-
tration of 5.0 µg/mL when infecting TZM-bl cells [12]; this
concentration neutralizes macrophage-tropic viruses but not
R5 T-cell–tropic viruses. No Env showed any (<2% infection)
ability to infect cells expressing low levels of CD4 as compared to
their infectivity on cells expressing high levels of CD4 (Figure 2B),
and they were also resistant to inhibition by sCD4 (Figure 2D).
In addition, all pseudotyped viruses were inhibited by the CCR5
antagonist maraviroc, and therefore all isolated Env used CCR5
as the coreceptor. Taken together, all Env tested from rebound
virus from all subjects had a phenotype consistent with that of
R5 T-cell–tropic virus.
DISCUSSION
In this report, we describe 2 key features of the initial virus that
rebounds from the latent or low-level viremia reservoir after
therapy discontinuation. These features are relevant to develop-
ing strategies of HIV-1 eradication because they are features of
the first virus that must be targeted. We asked what the entry
phenotype was of this virus, to determine what cell type it
had been predominantly replicating in at the time therapy
was initiated and/or it entered the latent reservoir. In addition,
we examined the complexity of the rebound population as a
measure of the minimum number of viruses that rebound
from the reservoir and become detected in the blood. The genet-
ic diversity of the viral reservoir and rebound virus has been de-
bated but it is perceived to be low and to be primarily clonal or
multiclonal [13, 14]. Our results are consistent with the obser-
vation of Rothenberger et al [4], who proposed a multifocal
model of virus reactivation. Counting major lineages with
both deep sequencing and SGA, we observed a mean of 3.1
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Figure 1. Sample/subject information and phylogenetic analysis of env sequences, using a deep-sequencing approach. A, Sample and subject information includes a key
indicating the subjects from whom samples were obtained, as well as nadir CD4+ T-cell counts, by category, over the course of care, CD4+ T-cell counts at the time of sampling,
and viral loads. B, Comparison of the time to a rebound in virus level among samples. In the majority of subjects, we were able to analyze the first sample in which virus was
detected or a sample very close to rebound detection. C, Comparison of the minimum number of major lineages represented in both deep-sequencing phylogenetic analysis and
single-genome amplification (SGA) phylogenetic analysis. D, Phylogenetic trees, created in FigTree, of the sequenced samples were produced using deep sequencing with
Primer ID and are presented so all samples are on the same scale. Abbreviation: NA, not applicable.
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distinct lineages, which suggests a minimum of 3 viruses re-
bounding within a short period after treatment interruption.
While this is significantly less than the 5–25 rebound/founder
viruses suggested by Rothenberger et al [4], when we reanalyzed
the sequence data from that study for the 3 subjects with SGA of
virion RNA by using the same criteria as used in this report, we
found that the mean number of distinct lineages was 3.3, similar
to what we observed (Supplementary Methods). However, since
Figure 2. Phylogenetic analysis of env sequences and tropism determination results. A, Phylogenetic tree, created using MEGA, of the sequences of subject 43 656 for the
sample obtained before therapy (R0; closed circles) and after the rebound in virus load (R1; open circles), generated using SGA. Cloned and tropism-analyzed env sequences are
marked with an asterisk. B–D, Tissue-culture assay results, using pseudotyped virus to define viral entry tropism phenotypes. The relative infectivity of pseudoviruses (red bars;
gray bars denote controls) was determined using Affinofile cells induced to expressing low levels of CD4 as compared to infection at high levels of CD4 (B). The relative
infectivity of all pseudotyped virus was <2% and indicates T-cell tropism. The relative infectivity of pseudovirus in the presence of CCR5 antagonist, maraviroc (MVC; red
bars; gray bars denote controls), showed nearly complete inhibition of all pseudotyped viruses and indicates use of CCR5 (C). The relative infectivity of TZM-bl cells by pseu-
dotyped virus in the presence of soluble CD4 (sCD4; purple bars; gray bars denote controls) showed resistance to inhibition by all pseudotype viruses, which further confirms a
T-cell–tropic phenotype (D).
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we did not count potential recombinants in our analysis, this is
a minimum estimate.
The number of rebound viruses could be affected by factors that
affect viral reservoir size, such as ART duration and time to ART
initiation after infection, but such data are not available for these
subjects. Reservoir size, as measured by cell-associated viral RNA
and DNA, has been shown to be correlated with set point after
therapy discontinuation [15]. Sample R2 had one of the lowest
sequence diversities (0.59%) and took the longest to have a mea-
surable rebound virus population, but we only analyzed one sub-
ject for whom >4 weeks passed before rebound was detected.
The use of viral outgrowth assays from subjects receiving
therapy after isolation of resting CD4+ T cells and reactivation
in culture has established this cell type as a reservoir for HIV-1
latency [1–3].We sought to evaluate the rebound virus popula-
tion by using entry phenotype. Distinct lineages of HIV-1 can
evolve the ability to use low levels of CD4 for entry, but these
have been found primarily in the cerebral spinal fluid; presum-
ably, this localized evolution is due to selective pressure to en-
hance replication in cells such as macrophages, which express
low levels of CD4. Here we assessed the CD4 entry phenotype
in conjunction with sCD4 sensitivity (a feature of low CD4-
using Env) to determine that rebound viruses needed high levels
of CD4 for efficient entry (Figure 2B). Sensitivity to inhibition
by maraviroc of all Env showed that all of the viruses used CCR5
(Figure 2C), making these viruses R5 T-cell tropic. On the basis
of this phenotypic characterization, we can conclude that re-
bound virus was adapted to replicating in CD4+ T cells at the
time the reservoir was formed. These results do not define the
cell type that harbored the latent virus before rebound (T cells
or macrophages), but these results exclude the possibility that
rebound virus was replicating extensively in a myeloid cell lin-
eage before latency, since this would have selected for the ability
to use low levels of CD4 for entry. It should be noted, however,
that viral rebound in isolated compartments of the body, such
as the brain, or viruses released later from smaller reservoirs
could have phenotypes that are distinct from that of the initial
rebound virus that predominates in the blood.
In summary, we have shown that the early rebound virus is
more diverse than previously thought. Additionally, we were
able to show that all virus isolates from the plasma used CCR5
and required high levels of CD4 for entry and therefore were
R5 T-cell tropic. This excludes a population of virus replicating
in myeloid cells as a significant contributor to the viral reservoir
that repopulates blood early after therapy discontinuation.
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